Search Results 1201-1210 of 17104 for monoclonal antibody

1. Respiratory syncytial virus vaccine, adjuvanted (intramuscular route) - Mayo Clinic

   It works by causing your body to produce its own protection (antibodies) against the disease. Respiratory syncytial virus can cause serious breathing ...

2. Sharing Mayo Clinic: Back from the brink

   Mayo Clinic Laboratories' comprehensive approach to targeted antibody testing played a crucial and lifesaving role in moving Sheila Lewis to recovery from ...

3. A Study to Evaluate AFPᶜ³³²T in Advanced HCC - Mayo Clinic

   Prior cancer-directed immunotherapy within 4 weeks, including monoclonal antibodies against PD-1 receptor or ligand;; Use of an experimental vaccine within 2 ...

4. A Study of TAK-981 in Combination with Rituximab in Participants with Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   iNHL (including FL of grades 1-3A and marginal zone lymphoma) refractory to rituximab or to any other anti-CD20 monoclonal antibodies ... Prior anti-CD20 antibody ...

5. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

   Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis 11. Venetoclax within 4 days prior to leukapheresis 12. Idelalisib or duvelisib within ...

6. A Study to Evaluate Induction Chemotherapy with ABVD Followed by Brentuximab Vedotin Consolidation in Previously-untreated, Non-bulky Stage I or II Hodgkin Lymphoma - Mayo Clinic

   For this research study, the use of brentuximab vedotin in newly diagnosed Hodgkin lymphoma is considered investigational. Brentuximab vedotin is an antibody ...

7. Hepatitis b immune globulin (intramuscular route, intravenous route) - Mayo Clinic

   Sexual partners of persons with hepatitis B. Persons who may be exposed to the virus by means of blood, blood products, or human bites, such as health care ...

8. CTX131 in Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Concurrent systemic treatment with an anticancer biologic (e.g., monoclonal antibody) within 30 days prior to CTX131 infusion or with a non-biological ...

9. A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma - Mayo Clinic

   and immunosuppressant monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of pirtobrutinib. In addition, no ...

10. Study of Oraxol and Pembrolizumab in Subjects with Advanced Solid Tumors - Mayo Clinic

    - Chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosurea, mitomycin-C, targeted therapy, and radiation) ≤ 28 ...